Cargando…

Multi-omic machine learning predictor of breast cancer therapy response

Breast cancers are complex ecosystems of malignant cells and the tumour microenvironment(1). The composition of these tumour ecosystems and interactions within them contribute to responses to cytotoxic therapy(2). Efforts to build response predictors have not incorporated this knowledge. We collecte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sammut, Stephen-John, Crispin-Ortuzar, Mireia, Chin, Suet-Feung, Provenzano, Elena, Bardwell, Helen A., Ma, Wenxin, Cope, Wei, Dariush, Ali, Dawson, Sarah-Jane, Abraham, Jean E., Dunn, Janet, Hiller, Louise, Thomas, Jeremy, Cameron, David A., Bartlett, John M. S., Hayward, Larry, Pharoah, Paul D., Markowetz, Florian, Rueda, Oscar M., Earl, Helena M., Caldas, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791834/ https://www.ncbi.nlm.nih.gov/pubmed/34875674 http://dx.doi.org/10.1038/s41586-021-04278-5

Ejemplares similares

Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers
por: Chin, Suet-Feung, et al.
Publicado: (2018)

Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers
por: Callari, Maurizio, et al.
Publicado: (2017)

Breast tumor microenvironment structures are associated with genomic features and clinical outcome
por: Danenberg, Esther, et al.
Publicado: (2022)

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial
por: Ali, H. R., et al.
Publicado: (2017)

Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts
por: Callari, Maurizio, et al.
Publicado: (2018)

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
por: Pereira, Bernard, et al.
Publicado: (2016)

Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
por: Pereira, Bernard, et al.
Publicado: (2016)

Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer
por: Ali, H. Raza, et al.
Publicado: (2016)

Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort
por: Mukherjee, A., et al.
Publicado: (2018)

A Prognostic Gene Signature for Metastasis-Free Survival of Triple Negative Breast Cancer Patients
por: Lee, UnJin, et al.
Publicado: (2013)

Master regulators of FGFR2 signalling and breast cancer risk
por: Fletcher, Michael N. C., et al.
Publicado: (2013)

DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation
por: Batra, Rajbir Nath, et al.
Publicado: (2021)

Dynamics of breast cancer relapse reveal late recurring ER-positive genomic subgroups
por: Rueda, Oscar M., et al.
Publicado: (2019)

Genome-driven integrated classification of breast cancer validated in over 7,500 samples
por: Ali, H Raza, et al.
Publicado: (2014)

The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences
por: Pan, Jia-Wern, et al.
Publicado: (2020)

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer
por: Ali, H R, et al.
Publicado: (2012)

Prognostic Value of MammaPrint(®) in Invasive Lobular Breast Cancer
por: Beumer, Inès J., et al.
Publicado: (2016)

Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53‐associated features
por: Benor, Gal, et al.
Publicado: (2020)

Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance
por: Ali, H Raza, et al.
Publicado: (2011)

Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays
por: Blows, Fiona M., et al.
Publicado: (2016)

High Jet Multiplicity Physics at the LHC
por: Crispin Ortuzar, Mireia
Publicado: (2016)

The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2019)

Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
por: Ali, H. Raza, et al.
Publicado: (2016)

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA
por: Gao, Meiling, et al.
Publicado: (2019)

Tissue-specific and interpretable sub-segmentation of whole tumour burden on CT images by unsupervised fuzzy clustering
por: Rundo, Leonardo, et al.
Publicado: (2020)

A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer
por: Vollan, Hans Kristian Moen, et al.
Publicado: (2014)

Calling Sample Mix-Ups in Cancer Population Studies
por: Lynch, Andy G., et al.
Publicado: (2012)

Precision radiogenomics: fusion biopsies to target tumour habitats in vivo
por: Crispin-Ortuzar, Mireia, et al.
Publicado: (2021)

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial
por: Provenzano, E, et al.
Publicado: (2013)

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer
por: Murtaza, Muhammed, et al.
Publicado: (2015)

Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response
por: Georgopoulou, Dimitra, et al.
Publicado: (2021)

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

High-resolution array CGH clarifies events occurring on 8p in carcinogenesis
por: Cooke, Susanna L, et al.
Publicado: (2008)

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
por: Earl, H. M., et al.
Publicado: (2017)

Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean?
por: Earl, Helena, et al.
Publicado: (2015)

Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer
por: Ali, A M G, et al.
Publicado: (2011)

TOX3 Mutations in Breast Cancer
por: Jones, James Owain, et al.
Publicado: (2013)

The pitfalls of platform comparison: DNA copy number array technologies assessed
por: Curtis, Christina, et al.
Publicado: (2009)

Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer
por: Martin-Gonzalez, Paula, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ue74acma7u5fvguco0sc812b01